Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam

Yonsei University Health System (YUHS)

Status: Completed

Conditions: Patients Undergoing Spine Surgery

Treatments: Drug: Propfol group; Drug: Remimazolam group

Study type: Interventional

Funder types: Other

Identifiers

NCT04994704

3-2021-0216

Details and patient eligibility

About

Remimazolam is a ultra-short-acting benzodiazepine, and unlike conventional benzodiazepine drugs, it is rapidly metabolized in plasma and not accumulates in the body for long periods of infusion or even with high dose administration. In addition, it has no injection pain and infusion syndrome compared with propofol. In particular, there is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. Therefore, rhe purpose of the study is to compare poetoperative quality of recovery (QoR)-15 scores according to the use of anesthetics for total intravenous anesthesia in the cervical spine surgery with intraoperative neurophysiological monitoring.

Enrollment: 73 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adult patients who aged 20-70 years with ASA-PS 1-3,
• diagnosed of ossification of the posterior longitudinal ligament or cervical spondylotic myelopathy
• intraoperative neurophysiological monitoring.

Exclusion criteria

• Tolerance or hypersensitivity to benzodiazepine or propofol
• Dependence or addiction to psychotropic drugs or alcohol
• Pregnant women, subjects who lack the ability to make decisions and susceptible to voluntary participation decisions

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

73 participants in 2 patient groups

Propofol group

Experimental group

Description:

Propofol based total intravenous anesthesia

Treatment:

Drug: Propfol group

Remimazolam group

Active Comparator group

Description:

Remimazolam based total intravenous anesthesia

Treatment:

Drug: Remimazolam group